Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression.

ABSTRACT:

Purpose

Immunotherapy plays an important role in non-small cell lung cancer (NSCLC); in particular, immune checkpoint inhibitors (ICIs) therapy has good therapeutic effects in PD-L1-positive patients. This study aims to screen NSCLC patients with PD-L1-positive expression and select effective biomarkers for ICI immunotherapy.

Methods

Collected tumor samples from the Affiliated Cancer Hospital of Xinjiang Medical University and 117 patients with stage III-IV NSCLC were included in the study. All patients were on first- or second-line therapy and not on targeted therapy. Based on the molecular profiles and clinical features, we screened biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression.

Results

117 NSCLC patients receiving ICI

SUBMITTER: Zhu X 

PROVIDER: S-EPMC10587271 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature